<SEC-DOCUMENT>0000064803-21-000036.txt : 20211209
<SEC-HEADER>0000064803-21-000036.hdr.sgml : 20211209
<ACCEPTANCE-DATETIME>20211209064317
ACCESSION NUMBER:		0000064803-21-000036
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20211209
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20211209
DATE AS OF CHANGE:		20211209

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CVS HEALTH Corp
		CENTRAL INDEX KEY:			0000064803
		STANDARD INDUSTRIAL CLASSIFICATION:	RETAIL-DRUG STORES AND PROPRIETARY STORES [5912]
		IRS NUMBER:				050494040
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-01011
		FILM NUMBER:		211480236

	BUSINESS ADDRESS:	
		STREET 1:		ONE CVS DR.
		CITY:			WOONSOCKET
		STATE:			RI
		ZIP:			02895
		BUSINESS PHONE:		4017651500

	MAIL ADDRESS:	
		STREET 1:		ONE CVS DR.
		CITY:			WOONSOCKET
		STATE:			RI
		ZIP:			02895

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CVS CAREMARK CORP
		DATE OF NAME CHANGE:	20070509

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CVS/CAREMARK CORP
		DATE OF NAME CHANGE:	20070322

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CVS CORP
		DATE OF NAME CHANGE:	19970128
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>cvs-20211209.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:808506d9-5561-437f-804a-f951434e5e2c,g:b02a37d0-9816-4b0a-89e0-a8785715b411,d:fde05c99ddd84aa3b7f4fc82594f5c43--><html xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>cvs-20211209</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ideab86f3595e4e809f335201713c0416_D20211209-20211209" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmZkZTA1Yzk5ZGRkODRhYTNiN2Y0ZmM4MjU5NGY1YzQzL3NlYzpmZGUwNWM5OWRkZDg0YWEzYjdmNGZjODI1OTRmNWM0M180L2ZyYWc6OWFlNWRmMGU5YTYyNDQyY2I2ZDQ0NjJmMTVjM2Y1ZDkvdGFibGU6NzIxOTg2NzIwYWNhNDQ5MmFkMzU4ZTI4NDhjYjE3Y2IvdGFibGVyYW5nZTo3MjE5ODY3MjBhY2E0NDkyYWQzNThlMjg0OGNiMTdjYl8yLTEtMS0xLTQ0ODEx_50b0e279-88b2-46e6-b18b-6ed6344d1bf4">0000064803</ix:nonNumeric><ix:nonNumeric contextRef="ideab86f3595e4e809f335201713c0416_D20211209-20211209" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmZkZTA1Yzk5ZGRkODRhYTNiN2Y0ZmM4MjU5NGY1YzQzL3NlYzpmZGUwNWM5OWRkZDg0YWEzYjdmNGZjODI1OTRmNWM0M180L2ZyYWc6OWFlNWRmMGU5YTYyNDQyY2I2ZDQ0NjJmMTVjM2Y1ZDkvdGFibGU6NzIxOTg2NzIwYWNhNDQ5MmFkMzU4ZTI4NDhjYjE3Y2IvdGFibGVyYW5nZTo3MjE5ODY3MjBhY2E0NDkyYWQzNThlMjg0OGNiMTdjYl8zLTEtMS0xLTQ0ODEx_ac003abf-35c2-4c8f-9aa5-7e13e4f2fe72">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="cvs-20211209.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ideab86f3595e4e809f335201713c0416_D20211209-20211209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-09</xbrli:startDate><xbrli:endDate>2021-12-09</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ifde05c99ddd84aa3b7f4fc82594f5c43_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="ideab86f3595e4e809f335201713c0416_D20211209-20211209" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmZkZTA1Yzk5ZGRkODRhYTNiN2Y0ZmM4MjU5NGY1YzQzL3NlYzpmZGUwNWM5OWRkZDg0YWEzYjdmNGZjODI1OTRmNWM0M18xL2ZyYWc6OTU3ZjcyNDA0NmZhNDNkNzljN2I1MTNjM2JlOGQzOGQvdGV4dHJlZ2lvbjo5NTdmNzI0MDQ2ZmE0M2Q3OWM3YjUxM2MzYmU4ZDM4ZF8xMzc0_7b501f36-cdc9-4786-87ec-0445cc3cd6b4">8-K</ix:nonNumeric> </span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934</span></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:71.773%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.027%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date of Report (Date of earliest event reported):</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ideab86f3595e4e809f335201713c0416_D20211209-20211209" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOmZkZTA1Yzk5ZGRkODRhYTNiN2Y0ZmM4MjU5NGY1YzQzL3NlYzpmZGUwNWM5OWRkZDg0YWEzYjdmNGZjODI1OTRmNWM0M18xL2ZyYWc6OTU3ZjcyNDA0NmZhNDNkNzljN2I1MTNjM2JlOGQzOGQvdGFibGU6ODI4N2JmMTg4ODBhNDMxNWFiOTJjZTIxN2M1YWEyM2MvdGFibGVyYW5nZTo4Mjg3YmYxODg4MGE0MzE1YWI5MmNlMjE3YzVhYTIzY18wLTEtMS0xLTQ0ODEx_bac45ecc-245d-41e3-8e8d-559129c55d0e">December 9, 2021</ix:nonNumeric></span></td></tr></table></div><div style="text-align:center"><img src="cvs-20211209_g1.jpg" alt="cvs-20211209_g1.jpg" style="height:19px;margin-bottom:5pt;vertical-align:text-bottom;width:104px"/></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ideab86f3595e4e809f335201713c0416_D20211209-20211209" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmZkZTA1Yzk5ZGRkODRhYTNiN2Y0ZmM4MjU5NGY1YzQzL3NlYzpmZGUwNWM5OWRkZDg0YWEzYjdmNGZjODI1OTRmNWM0M18xL2ZyYWc6OTU3ZjcyNDA0NmZhNDNkNzljN2I1MTNjM2JlOGQzOGQvdGV4dHJlZ2lvbjo5NTdmNzI0MDQ2ZmE0M2Q3OWM3YjUxM2MzYmU4ZDM4ZF8xMzc1_8b0c809c-1f5f-42f9-b75a-7b9a786205b4">CVS HEALTH CORP</ix:nonNumeric>ORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ideab86f3595e4e809f335201713c0416_D20211209-20211209" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmZkZTA1Yzk5ZGRkODRhYTNiN2Y0ZmM4MjU5NGY1YzQzL3NlYzpmZGUwNWM5OWRkZDg0YWEzYjdmNGZjODI1OTRmNWM0M18xL2ZyYWc6OTU3ZjcyNDA0NmZhNDNkNzljN2I1MTNjM2JlOGQzOGQvdGFibGU6OGVkZmRiMTUyOWM1NDlmMzg1ZWVjNGRlODYxN2QxMGIvdGFibGVyYW5nZTo4ZWRmZGIxNTI5YzU0OWYzODVlZWM0ZGU4NjE3ZDEwYl8wLTAtMS0xLTQ0ODEx_c0920fed-dd4b-4b05-9f60-5ceda3ccf9da">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ideab86f3595e4e809f335201713c0416_D20211209-20211209" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmZkZTA1Yzk5ZGRkODRhYTNiN2Y0ZmM4MjU5NGY1YzQzL3NlYzpmZGUwNWM5OWRkZDg0YWEzYjdmNGZjODI1OTRmNWM0M18xL2ZyYWc6OTU3ZjcyNDA0NmZhNDNkNzljN2I1MTNjM2JlOGQzOGQvdGFibGU6OGVkZmRiMTUyOWM1NDlmMzg1ZWVjNGRlODYxN2QxMGIvdGFibGVyYW5nZTo4ZWRmZGIxNTI5YzU0OWYzODVlZWM0ZGU4NjE3ZDEwYl8wLTEtMS0xLTQ0ODEx_1f3b9081-6064-4bda-b51d-58969f60bae5">001-01011</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ideab86f3595e4e809f335201713c0416_D20211209-20211209" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmZkZTA1Yzk5ZGRkODRhYTNiN2Y0ZmM4MjU5NGY1YzQzL3NlYzpmZGUwNWM5OWRkZDg0YWEzYjdmNGZjODI1OTRmNWM0M18xL2ZyYWc6OTU3ZjcyNDA0NmZhNDNkNzljN2I1MTNjM2JlOGQzOGQvdGFibGU6OGVkZmRiMTUyOWM1NDlmMzg1ZWVjNGRlODYxN2QxMGIvdGFibGVyYW5nZTo4ZWRmZGIxNTI5YzU0OWYzODVlZWM0ZGU4NjE3ZDEwYl8wLTItMS0xLTQ0ODEx_311fae58-c9a5-4b0a-a14f-5e9514212dab">05-0494040</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(State or other jurisdiction of incorporation)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Commission <br/>File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(IRS Employer <br/>Identification No.)</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ideab86f3595e4e809f335201713c0416_D20211209-20211209" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmZkZTA1Yzk5ZGRkODRhYTNiN2Y0ZmM4MjU5NGY1YzQzL3NlYzpmZGUwNWM5OWRkZDg0YWEzYjdmNGZjODI1OTRmNWM0M18xL2ZyYWc6OTU3ZjcyNDA0NmZhNDNkNzljN2I1MTNjM2JlOGQzOGQvdGV4dHJlZ2lvbjo5NTdmNzI0MDQ2ZmE0M2Q3OWM3YjUxM2MzYmU4ZDM4ZF8xMzc2_0973c498-6e59-4cf8-8262-10169fc2cd1d">One CVS Drive</ix:nonNumeric>, <ix:nonNumeric contextRef="ideab86f3595e4e809f335201713c0416_D20211209-20211209" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmZkZTA1Yzk5ZGRkODRhYTNiN2Y0ZmM4MjU5NGY1YzQzL3NlYzpmZGUwNWM5OWRkZDg0YWEzYjdmNGZjODI1OTRmNWM0M18xL2ZyYWc6OTU3ZjcyNDA0NmZhNDNkNzljN2I1MTNjM2JlOGQzOGQvdGV4dHJlZ2lvbjo5NTdmNzI0MDQ2ZmE0M2Q3OWM3YjUxM2MzYmU4ZDM4ZF8xMzc3_01f41b2e-5e5a-40d4-a889-43840138d94c">Woonsocket</ix:nonNumeric>, <ix:nonNumeric contextRef="ideab86f3595e4e809f335201713c0416_D20211209-20211209" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmZkZTA1Yzk5ZGRkODRhYTNiN2Y0ZmM4MjU5NGY1YzQzL3NlYzpmZGUwNWM5OWRkZDg0YWEzYjdmNGZjODI1OTRmNWM0M18xL2ZyYWc6OTU3ZjcyNDA0NmZhNDNkNzljN2I1MTNjM2JlOGQzOGQvdGV4dHJlZ2lvbjo5NTdmNzI0MDQ2ZmE0M2Q3OWM3YjUxM2MzYmU4ZDM4ZF8xMzc4_8c76a650-8cf9-4e85-ad16-4136b288d30d">Rhode Island</ix:nonNumeric>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ideab86f3595e4e809f335201713c0416_D20211209-20211209" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmZkZTA1Yzk5ZGRkODRhYTNiN2Y0ZmM4MjU5NGY1YzQzL3NlYzpmZGUwNWM5OWRkZDg0YWEzYjdmNGZjODI1OTRmNWM0M18xL2ZyYWc6OTU3ZjcyNDA0NmZhNDNkNzljN2I1MTNjM2JlOGQzOGQvdGV4dHJlZ2lvbjo5NTdmNzI0MDQ2ZmE0M2Q3OWM3YjUxM2MzYmU4ZDM4ZF8xMzc5_2c22e312-e630-4744-be40-8a15aa665479">02895</ix:nonNumeric> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Address of principal executive offices)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(Zip Code)</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Registrant&#8217;s telephone number, including area code: &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="ideab86f3595e4e809f335201713c0416_D20211209-20211209" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmZkZTA1Yzk5ZGRkODRhYTNiN2Y0ZmM4MjU5NGY1YzQzL3NlYzpmZGUwNWM5OWRkZDg0YWEzYjdmNGZjODI1OTRmNWM0M18xL2ZyYWc6OTU3ZjcyNDA0NmZhNDNkNzljN2I1MTNjM2JlOGQzOGQvdGV4dHJlZ2lvbjo5NTdmNzI0MDQ2ZmE0M2Q3OWM3YjUxM2MzYmU4ZDM4ZF8xMzgz_9f5ba687-0cb3-4da6-81ef-4f4d6a60b2e5">401</ix:nonNumeric>) <ix:nonNumeric contextRef="ideab86f3595e4e809f335201713c0416_D20211209-20211209" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmZkZTA1Yzk5ZGRkODRhYTNiN2Y0ZmM4MjU5NGY1YzQzL3NlYzpmZGUwNWM5OWRkZDg0YWEzYjdmNGZjODI1OTRmNWM0M18xL2ZyYWc6OTU3ZjcyNDA0NmZhNDNkNzljN2I1MTNjM2JlOGQzOGQvdGV4dHJlZ2lvbjo5NTdmNzI0MDQ2ZmE0M2Q3OWM3YjUxM2MzYmU4ZDM4ZF8xMzgw_9cd21e76-4148-419f-acdd-52bff4715f98">765-1500</ix:nonNumeric> </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Former name or former address, if changed since last report:&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">N/A</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ideab86f3595e4e809f335201713c0416_D20211209-20211209" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmZkZTA1Yzk5ZGRkODRhYTNiN2Y0ZmM4MjU5NGY1YzQzL3NlYzpmZGUwNWM5OWRkZDg0YWEzYjdmNGZjODI1OTRmNWM0M18xL2ZyYWc6OTU3ZjcyNDA0NmZhNDNkNzljN2I1MTNjM2JlOGQzOGQvdGV4dHJlZ2lvbjo5NTdmNzI0MDQ2ZmE0M2Q3OWM3YjUxM2MzYmU4ZDM4ZF8xMzcz_28f1be83-ead2-43d7-8b0b-84615347085e">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ideab86f3595e4e809f335201713c0416_D20211209-20211209" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmZkZTA1Yzk5ZGRkODRhYTNiN2Y0ZmM4MjU5NGY1YzQzL3NlYzpmZGUwNWM5OWRkZDg0YWEzYjdmNGZjODI1OTRmNWM0M18xL2ZyYWc6OTU3ZjcyNDA0NmZhNDNkNzljN2I1MTNjM2JlOGQzOGQvdGV4dHJlZ2lvbjo5NTdmNzI0MDQ2ZmE0M2Q3OWM3YjUxM2MzYmU4ZDM4ZF8xMzgx_185948a7-60a6-4be0-962b-94f4226bd6a3">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ideab86f3595e4e809f335201713c0416_D20211209-20211209" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmZkZTA1Yzk5ZGRkODRhYTNiN2Y0ZmM4MjU5NGY1YzQzL3NlYzpmZGUwNWM5OWRkZDg0YWEzYjdmNGZjODI1OTRmNWM0M18xL2ZyYWc6OTU3ZjcyNDA0NmZhNDNkNzljN2I1MTNjM2JlOGQzOGQvdGV4dHJlZ2lvbjo5NTdmNzI0MDQ2ZmE0M2Q3OWM3YjUxM2MzYmU4ZDM4ZF8xMzgy_1e627925-761f-4801-9be4-0b56d1df1dc1">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ideab86f3595e4e809f335201713c0416_D20211209-20211209" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmZkZTA1Yzk5ZGRkODRhYTNiN2Y0ZmM4MjU5NGY1YzQzL3NlYzpmZGUwNWM5OWRkZDg0YWEzYjdmNGZjODI1OTRmNWM0M18xL2ZyYWc6OTU3ZjcyNDA0NmZhNDNkNzljN2I1MTNjM2JlOGQzOGQvdGV4dHJlZ2lvbjo5NTdmNzI0MDQ2ZmE0M2Q3OWM3YjUxM2MzYmU4ZDM4ZF8xMzg0_dd07e0d3-45b9-4bb2-975f-9da072a5e5e6">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:33.759%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.396%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ideab86f3595e4e809f335201713c0416_D20211209-20211209" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmZkZTA1Yzk5ZGRkODRhYTNiN2Y0ZmM4MjU5NGY1YzQzL3NlYzpmZGUwNWM5OWRkZDg0YWEzYjdmNGZjODI1OTRmNWM0M18xL2ZyYWc6OTU3ZjcyNDA0NmZhNDNkNzljN2I1MTNjM2JlOGQzOGQvdGFibGU6YmY5NTA1MDJhNzNiNGI4Mjg0MWI2ZGQ3ZjFiZDFlMjgvdGFibGVyYW5nZTpiZjk1MDUwMmE3M2I0YjgyODQxYjZkZDdmMWJkMWUyOF8xLTAtMS0xLTQ0ODEx_62cad84b-6145-4a40-b525-fb62a9ae8469">Common Stock, par value $0.01 per share</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ideab86f3595e4e809f335201713c0416_D20211209-20211209" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmZkZTA1Yzk5ZGRkODRhYTNiN2Y0ZmM4MjU5NGY1YzQzL3NlYzpmZGUwNWM5OWRkZDg0YWEzYjdmNGZjODI1OTRmNWM0M18xL2ZyYWc6OTU3ZjcyNDA0NmZhNDNkNzljN2I1MTNjM2JlOGQzOGQvdGFibGU6YmY5NTA1MDJhNzNiNGI4Mjg0MWI2ZGQ3ZjFiZDFlMjgvdGFibGVyYW5nZTpiZjk1MDUwMmE3M2I0YjgyODQxYjZkZDdmMWJkMWUyOF8xLTEtMS0xLTQ0ODEx_833b42cd-b239-481d-be14-ba0cae3431e5">CVS</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ideab86f3595e4e809f335201713c0416_D20211209-20211209" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmZkZTA1Yzk5ZGRkODRhYTNiN2Y0ZmM4MjU5NGY1YzQzL3NlYzpmZGUwNWM5OWRkZDg0YWEzYjdmNGZjODI1OTRmNWM0M18xL2ZyYWc6OTU3ZjcyNDA0NmZhNDNkNzljN2I1MTNjM2JlOGQzOGQvdGFibGU6YmY5NTA1MDJhNzNiNGI4Mjg0MWI2ZGQ3ZjFiZDFlMjgvdGFibGVyYW5nZTpiZjk1MDUwMmE3M2I0YjgyODQxYjZkZDdmMWJkMWUyOF8xLTItMS0xLTQ0ODEx_7111304a-838d-4fcf-a4f2-7fde8b1f202d">New York Stock Exchange</ix:nonNumeric></span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:96.999%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.701%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ideab86f3595e4e809f335201713c0416_D20211209-20211209" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmZkZTA1Yzk5ZGRkODRhYTNiN2Y0ZmM4MjU5NGY1YzQzL3NlYzpmZGUwNWM5OWRkZDg0YWEzYjdmNGZjODI1OTRmNWM0M18xL2ZyYWc6OTU3ZjcyNDA0NmZhNDNkNzljN2I1MTNjM2JlOGQzOGQvdGFibGU6MDZjOGRjYmI5MzNkNDhjYzlhOGVlYWM0MWVhN2IxMjMvdGFibGVyYW5nZTowNmM4ZGNiYjkzM2Q0OGNjOWE4ZWVhYzQxZWE3YjEyM18wLTEtMS0xLTQ0ODEx_d669873c-9ea4-4fee-82d2-7a889341d821">&#9744;</ix:nonNumeric></span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#9744;</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ifde05c99ddd84aa3b7f4fc82594f5c43_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 7 - Regulation FD</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 7.01   Regulation FD Disclosure.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with its 2021 Investor Day, on December 9, 2021, CVS Health Corporation&#160;issued a press release that, among other things, discussed its strategic priorities, updated its 2021 full year projections and provided initial projections for 2022. A copy of that press release is furnished herewith as Exhibit 99.1 and hereby incorporated in this Item 7.01 by reference.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information in this Current Report on Form 8-K shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934 (as amended, the &#8220;Exchange Act&#8221;) or otherwise subject to the liabilities of that Section, and shall not be or be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 9 - Financial Statements and Exhibits</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01   Financial Statements and Exhibits.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibits</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exhibits to this Current Report on Form 8-K are as follows: </span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX TO EXHIBITS</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.111%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.678%"></td><td style="width:0.1%"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">99.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="cvs_ex99x1xinvestorday.htm">Press Release of CVS Health Corporation dated December 9, 2021</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">104</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document.</span></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.309%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.443%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.709%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CVS HEALTH CORPORATION</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 9, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">/s/ Shawn M. Guertin</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shawn M. Guertin</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and Chief Financial Officer</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>cvs_ex99x1xinvestorday.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i304fca8bee2e416e8de1ae6be930168c_1"></div><div style="min-height:45pt;width:100%"><div style="padding-left:202.5pt;text-align:right;text-indent:-184.5pt"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;99.1</font></div><div style="text-align:right"><font><br></font></div></div><div style="text-align:right"><img alt="cvslogoa.jpg" src="cvslogoa.jpg" style="height:97px;margin-bottom:5pt;vertical-align:text-bottom;width:385px"></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CVS Health Presents Strategy for Revolutionizing Consumer Health Experience While Driving Profitable Growth</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Advancement of Health Services and Primary Care Capabilities Will Augment Performance in Foundational Businesses While Creating New Opportunities in High-Growth Markets</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Updating 2021 Adjusted EPS Guidance to at Least $8.00&#59; Initiating 2022 Guidance for Adjusted EPS of </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">$8.10 - $8.30 and GAAP EPS of $7.04 - $7.24 </font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Returning Capital to Shareholders Through 10% Dividend Raise and $10 Billion Share Repurchase Program</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">WOONSOCKET, R.I., December 9, 2021 &#8211; Today at its 2021 Investor Day, the CVS Health (NYSE&#58; CVS) leadership team will present a strategy that capitalizes on the significant opportunity to make health care more convenient, personalized and affordable for consumers. Leaders will articulate how investing in high-growth areas of the business and introducing new health products, services and technologies will enhance shareholder value. The company will also provide greater visibility into its near- and long-term financial performance expectations.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;Now is the time to undertake our next major evolution and capitalize on our role as the leading health solutions company in America,&#8221; said CVS Health President and CEO Karen S. Lynch. &#8220;By leaning into our high-growth foundational businesses and expanding our reach in areas like health services and primary care, we have an opportunity to shift care to be more centered around the consumer while capturing a meaningfully greater portion of health care spend. Ultimately, this plan is only possible with our unique combination of assets which will allow us to lower costs, increase access to quality care and improve health outcomes for consumers, patients and members &#8211; while delivering superior results for shareholders.&#8221;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The CVS Health management team will focus on priority areas for strategic growth, including&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.15pt">Maximizing growth in the company&#8217;s foundational businesses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">by continuing to position its existing assets to deliver market-leading health solutions and focusing on high-growth opportunities.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.15pt">Advancing primary care delivery capabilities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">by guiding consumers across the care continuum to sites and to providers that meet their needs &#8211; both in person and virtually. This approach will complement the traditional provider network and continue to expand ways to utilize risk-based arrangements and value-based care. </font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.15pt">Optimizing the retail portfolio to serve as community health destinations </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">by pivoting the store footprint to focus on advanced primary care centers, enhanced HealthHUB locations and traditional CVS Pharmacy stores. As announced last month, the company will close approximately 900 stores over the next three years to reduce store density and ensure it has the right kinds of stores in the right locations for consumers and for the business. </font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.15pt">Launching new all-payer health products and services</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> which will diversify the company&#8217;s growth portfolio with new health solutions for employers, consumers and health plans. This will include the expansion of home health services, the launch of health-related subscription models for broader </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">populations, the commercialization of analytics and insights, and establishing all-payer and provider enablement services.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.15pt">Driving a digital-first, technology-forward approach</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">that will expand the company&#8217;s reach and engagement with its more than 35 million online members, launching new consumer-centric services and offerings, enhancing the customer experience and streamlining business operations &#8211; leading to higher customer satisfaction levels and lower costs. </font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.15pt">Enhancing omnichannel health services</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">to meet the needs of consumers when and where they want them, including at home, virtually and in the community. This will include execution of the company&#8217;s omnichannel pharmacy strategy, with integration across all fulfillment channels to make pharmacy interactions as personalized and seamless as possible. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">CVS Health leaders will discuss how a fully integrated company is creating measurable value for customers and shareholders. This includes highlighting a multi-year observational study of Aetna&#8217;s commercial self-funded business that shows consistent improvement in utilization and cost of care when the member has both Aetna medical and pharmacy benefits. Integrated members were associated with a sustained 3 &#8211; 6% decrease in per member per month medical costs over a three-year period. Members who filled prescriptions at CVS Pharmacy locations were associated with 6% higher adherence across important chronic conditions, including congestive heart disease, diabetes, and hypertension, and demonstrated at least a 40% higher level of engagement in supportive care management programs in 2020.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">CVS Health CFO and Executive Vice President Shawn Guertin will discuss the company&#8217;s 2022 financial outlook in detail, the company&#8217;s capital allocation strategy and its long-term outlook and growth targets. As part of its long-term growth trajectory, CVS Health is targeting a return to low double-digit adjusted EPS growth in 2024 and beyond.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;We have a strategic financial approach that will focus on a combination of foundational business growth, new sources of incremental value and strategic capital deployment in order to reach our long-term growth targets and drive shareholder returns,&#8221; Guertin said. &#8220;We will also continue to prudently manage our balance sheet, while deploying capital against growth areas such as capability-focused M&#38;A targets that will fit with our unique collection of assets and help accelerate our vision.&#8221;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">2021 Guidance</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The company is updating its 2021 full year projections&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.15pt">Total Revenues</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#58; at least $290.3 billion from a prior range of $286.5 to $290.3 billion </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.15pt">Adjusted Operating Income&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> at least $16.6 billion from a prior range of $16.4 to $16.6 billion </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.15pt">GAAP EPS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#58; $5.50 to $5.61 from a prior range of $5.46 to $5.67 </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.15pt">Adjusted EPS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#58; at least $8.00 from a prior range of $7.90 to $8.00</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.15pt">Cash Flow from Operations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#58; at least $13.5 billion from a prior range of $13.0 to $13.5 billion</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">2022 Guidance</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The company is initiating 2022 full year projections&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.15pt">Total Revenues</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#58; $304.0 to $309.0 billion</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.15pt">Adjusted Operating Income&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> $16.7 to $17.1 billion </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.15pt">Adjusted EPS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#58; $8.10 to $8.30</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.15pt">GAAP EPS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#58; $7.04 to $7.24</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.15pt">Cash Flow from Operations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#58; $12.5 to $13.0 billion</font></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Capital Deployment</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In addition, the company will increase its yearly dividend by 10%, from $2.00 to $2.20, effective with the next dividend distribution on February 1, 2022. The company also has authorized a $10 billion share repurchase program, which will be used to at least offset share count dilution in 2022. This is the first time CVS Health has increased its dividend or repurchased stock since 2017. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Investor Day Webcast</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The event will begin at 8&#58;00 AM ET. An audio and video webcast will be broadcast simultaneously on the Investor Relations portion of the CVS Health website at investors.cvshealth.com. Presentations and other accompanying material will be available on the website shortly before the event begins and archived for one year along with a replay of the event.</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">###</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">About CVS Health</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">CVS Health is the leading health solutions company, delivering care like no one else can. We reach more people and improve the health of communities across America through our local presence, digital channels and over 300,000 dedicated colleagues including more than 40,000 physicians, pharmacists, nurses, and nurse practitioners. Wherever and whenever people need us, we help them with their health whether that&#8217;s managing chronic diseases, staying compliant with their medications, or accessing affordable health and wellness services in the most convenient ways. We help people navigate the health care system and their personal health care by improving access, lowering costs and being a trusted partner for every meaningful moment of health. And we do it all with heart, each and every day. Learn more at www.cvshealth.com.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Cautionary Statement Concerning Forward-Looking Statements</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by or on behalf of CVS Health Corporation. Statements in this press release that are forward-looking include references to CVS Health Corporation&#8217;s priority areas for strategic growth, the 2022 financial outlook, long term growth targets, capital deployment, Ms. Lynch&#8217;s quotation and Mr. Guertin&#8217;s quotation, the information under the headings &#8220;2021 Guidance&#8221; and &#8220;2022 Guidance&#8221; and the information included in the endnotes and reconciliations.  By their nature, all forward-looking statements are not guarantees of future performance or results and are subject to risks and uncertainties that are difficult to predict and&#47;or quantify. Actual results may differ materially from those contemplated by the forward-looking statements due to the continuing uncertainties related to the COVID-19 pandemic, including the impact of new and existing variants on consumer behavior, health care utilization patterns and federal, state and local response to the pandemic, as well as the risks and uncertainties described in our Securities and Exchange Commission (&#8220;SEC&#8221;) filings, including those set forth in the Risk Factors section and under the heading &#8220;Cautionary Statement Concerning Forward-Looking Statements&#8221; in our most recently filed Annual Report on Form 10-K and our Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2021 and our current report on Form 8-K filed on November 18, 2021.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">You are cautioned not to place undue reliance on CVS Health&#8217;s forward-looking statements. CVS Health&#8217;s forward-looking statements are and will be based upon management&#8217;s then-current views and assumptions regarding future events and operating performance, and are applicable only as of the dates of such statements. CVS Health does not assume any duty to update or revise forward-looking statements, whether as a result of new information, future events, uncertainties or otherwise.</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Non-GAAP Financial Measures</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This press release contains certain non-GAAP financial measures, including adjusted operating income and adjusted earnings per share. In accordance with SEC regulations, you can find the definitions of the Non-GAAP items mentioned, as well as the reconciliations to the most directly comparable GAAP measures, below in this press release.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Media contact</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">T.J. Crawford</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">212-457-0583</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">CrawfordT2&#64;CVSHealth.com</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Investor contact</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Susie Lisa, CFA</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">401-770-4050</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Susan.Lisa&#64;CVSHealth.com</font></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</font></div><div><font><br></font></div></div></div><div id="i304fca8bee2e416e8de1ae6be930168c_4"></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Reconciliations of Non-GAAP Financial Measure to the Most Directly Comparable GAAP Financial Measures</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Adjusted Operating Income</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(Unaudited)</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company defines adjusted operating income as operating income (GAAP measure) excluding the impact of amortization of intangible assets and other items, if any, that neither relate to the ordinary course of the Company&#8217;s business nor reflect the Company&#8217;s underlying business performance, such as acquisition-related integration costs, store impairments, goodwill impairments, acquisition purchase price adjustments outside of measurement period, gains&#47;losses on divestitures and the receipt of amounts owed to the Company under the Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act of 2010 (collectively, the &#8220;ACA&#8221;) risk corridor program. The Company uses adjusted operating income as its principal measure of segment performance as it enhances the Company&#8217;s ability to compare past financial performance with current performance and analyze underlying business performance and trends. The consolidated measure is not determined in accordance with GAAP and should not be considered a substitute for, or superior to, the most directly comparable GAAP measure, consolidated operating income. The following are reconciliations of projected operating income to projected adjusted operating income&#58;</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.759%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.699%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ending </font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021E</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In&#160;millions</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Low</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">High</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Actual</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (GAAP measure)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:0.75pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,630&#160;</font></td><td style="background-color:#cceeff;border-top:0.75pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:0.75pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,830&#160;</font></td><td style="background-color:#cceeff;border-top:0.75pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:0.75pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,911&#160;</font></td><td style="background-color:#cceeff;border-top:0.75pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,260&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,260&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,341&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related integration costs </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">332&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Store impairments </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,200&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill impairment </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">431&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">431&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition purchase price adjustment outside of measurement period </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on divestiture of subsidiary </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(269)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receipt of fully reserved ACA risk corridor receivable </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(307)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted operating income </font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,620&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,620&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,008&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">_____________________________________________</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Acquisition-related integration costs relate to the Aetna acquisition.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">In connection with a planned closure of approximately 900 stores over the next three years, the Company expects to record an impairment charge in the fourth quarter of 2021 of between $1.0 billion to $1.2 billion. This charge relates to the write-down of operating lease right-of-use assets and property and equipment. The charge is included in the Retail&#47;LTC segment. The amount of this expected impairment charge is an estimate, and the actual charge may vary due to a variety of factors. </font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The goodwill impairment charge was recorded in the third quarter of 2021 in the long-term care (&#8220;LTC&#8221;) reporting unit within the Retail&#47;LTC segment.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">In June 2021, the Company received $61&#160;million related to a purchase price working capital adjustment for an acquisition completed during the first quarter of 2020. The resolution of this matter occurred subsequent to the acquisition accounting measurement period and is reflected within the Health Care Benefits segment.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(5)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">During the year ended December 31, 2020, the gain on divestiture of subsidiary represents the pre-tax gain on the sale of the Workers&#8217; Compensation business, which the Company sold on July 31, 2020 for approximately $850&#160;million. The gain on divestiture is reflected as a reduction in operating expenses in the Company&#8217;s consolidated statements of operations within the Health Care Benefits segment in the year ended December 31, 2020.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(6)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">During the year ended December 31, 2020, the Company received $313&#160;million owed to it under the ACA&#8217;s risk corridor program that was previously fully reserved for as payment was uncertain. After considering offsetting items such as the ACA&#8217;s minimum medical loss ratio (&#8220;MLR&#8221;) rebate requirements and premium taxes, the Company recognized pre-tax income of $307&#160;million in the Company&#8217;s consolidated statements of operations within the Health Care Benefits segment.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.759%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.699%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ending </font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022E</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021E</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In&#160;millions</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Low</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">High</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Midpoint</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (GAAP measure)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,870&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,220&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,730&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Non-GAAP adjustments&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,870&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,870&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,260&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related integration costs </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Store impairments </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,100&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill impairment </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">431&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition purchase price adjustment outside of measurement period </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted operating income </font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,740&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,090&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,620&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">            _____________________________________________</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Acquisition-related integration costs relate to the Aetna acquisition.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">In connection with a planned closure of approximately 900 stores over the next three years, the Company expects to record an impairment charge in the fourth quarter of 2021 of between $1.0 billion to $1.2 billion. This charge relates to the write-down of operating lease right-of-use assets and property and equipment. The charge is included in the Retail&#47;LTC segment. The amount of this expected impairment charge is an estimate, and the actual charge may vary due to a variety of factors. </font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The goodwill impairment charge was recorded in the third quarter of 2021 in the LTC reporting unit within the Retail&#47;LTC segment.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">In June 2021, the Company received $61&#160;million related to a purchase price working capital adjustment for an acquisition completed during the first quarter of 2020. The resolution of this matter occurred subsequent to the acquisition accounting measurement period and is reflected within the Health Care Benefits segment.</font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Adjusted Earnings Per Share</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(Unaudited)</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">GAAP diluted Earnings Per Share (&#8220;EPS&#8221;), Adjusted EPS, and Baseline Adjusted EPS respectively, are calculated by dividing income from continuing operations attributable to CVS Health, adjusted income from continuing operations attributable to CVS Health and baseline adjusted income from continuing operations attributable to CVS Health by the Company&#8217;s weighted average diluted shares outstanding. The Company defines adjusted income from continuing operations attributable to CVS Health as income from continuing operations attributable to CVS Health (GAAP measure) excluding the impact of amortization of intangible assets and other items, if any, that neither relate to the ordinary course of the Company&#8217;s business nor reflect the Company&#8217;s underlying business performance, such as acquisition-related integration costs, store impairments, goodwill impairments, acquisition purchase price adjustments outside of measurement period, gains&#47;losses on divestitures, receipt of amounts owed to the Company under the ACA risk corridor program, losses on early extinguishment of debt and the corresponding tax benefit or expense related to the items excluded from adjusted income from continuing operations attributable to CVS Health. Baseline adjusted income from continuing operations attributable to CVS Health also excludes from income from continuing operations attributable to CVS Health the impact of items that the Company cannot project for future periods such as realized capital gains and losses, changes in prior years&#8217; health care costs estimates, and includes an estimate of the full year incremental expense related to our minimum wage increase and the corresponding tax benefit or expense per share related to the such items excluded from or added to baseline Adjusted EPS above. The following are reconciliations of projected GAAP diluted EPS to projected Adjusted EPS and Baseline Adjusted EPS&#58;</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.554%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021E</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Low</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">High</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Actual</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In&#160;millions,&#160;except&#160;per&#160;share&#160;amounts</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total<br>Company</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Per<br>Common<br> Share</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total<br>Company</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Per<br>Common<br> Share</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total<br>Company</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Per<br>Common<br> Share</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations (GAAP measure)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,311&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.50&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,460&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.61&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,188&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.47&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Non-GAAP adjustments&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,260&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.70&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,260&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.70&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,341&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.78&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related integration costs </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.12&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.12&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">332&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.25&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Store impairments </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,200&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.90&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.75&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill impairment </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">431&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.33&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">431&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.33&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition purchase price adjustment outside of measurement period </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.05)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.05)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on divestiture of subsidiary </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(269)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.20)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receipt of fully reserved ACA risk corridor receivable </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(307)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.23)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on early extinguishment of debt </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(7)</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">468&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.35&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">468&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.35&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,440&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.09&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax impact of non-GAAP adjustments </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(8)</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,129)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.85)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,078)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.81)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(877)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.67)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receipt of ACA risk corridor receivable attributable to noncontrolling interest, net of tax </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.01&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted income from continuing operations attributable to CVS Heath </font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,640&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.00&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,640&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.00&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,860&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.50&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total baseline adjustments </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(9)</font></div></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.40)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.40)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Baseline adjusted EPS </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(9)</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.60&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.60&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average diluted shares outstanding</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,330&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,330&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,314&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:107%;position:relative;top:-3.5pt;vertical-align:baseline">  _____________________________________________</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Acquisition-related integration costs relate to the Aetna acquisition.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">In connection with a planned closure of approximately 900 stores over the next three years, the Company expects to record an impairment charge in the fourth quarter of 2021 of between $1.0 billion to $1.2 billion. This charge relates to the write down of operating lease right-of-use assets and property and </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">equipment. The charge is included in the Retail&#47;LTC segment. The amount of this expected impairment charge is an estimate, and the actual charge may vary due to a variety of factors. </font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The goodwill impairment charge was recorded in the third quarter of 2021 in the LTC reporting unit within the Retail&#47;LTC segment.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">In June 2021, the Company received $61 million related to a purchase price working capital adjustment for an acquisition completed during the first quarter of 2020. The resolution of this matter occurred subsequent to the acquisition accounting measurement period and is reflected within the Health Care Benefits segment.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(5)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">In 2020, gain on divestiture of subsidiary represents the pre-tax gain on the sale of the Workers&#8217; Compensation business, sold on July 31, 2020 for approximately $850&#160;million.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(6)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Reflects the receipt of $313 million owed to the Company under the ACA&#8217;s risk corridor program during October 2020 that was previously fully reserved for as payment was uncertain. After considering offsetting items such as the ACA&#8217;s MLR rebate requirements and premium taxes, the Company recognized pre-tax income of approximately $307 million within the Health Care Business during the fourth quarter of 2020. The portion of the ACA risk corridor payment attributable to noncontrolling interest was $12 million related to third party ownership interests in the Company's consolidated operating entities.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(7)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">During the year ending December 31, 2021, the loss on early extinguishment of debt relates to the Company&#8217;s repayment of approximately $2.0 billion of its outstanding senior notes in August 2021 pursuant to its tender offers for such senior notes, which resulted in a $363 million loss on the early extinguishment of debt in the third quarter of 2021, and the expected repayment of approximately $2.3 billion of its outstanding senior notes in December 2021 pursuant to its make-whole provision for such senior notes, which is expected to result in an estimated loss on the early extinguishment of debt in the fourth quarter of approximately $105 million. During the year ended December 31, 2020, the loss on early extinguishment of debt relates to the Company&#8217;s repayment of $4.5 billion of its outstanding senior notes in December 2020 pursuant to its tender offers for such senior notes and the Company&#8217;s repayment of $6.0 billion of its outstanding senior notes in August 2020 pursuant to its tender offer for such senior notes.  </font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(8)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Represents the corresponding tax benefit or expense related to the items excluded from Adjusted EPS above. The nature of each non-GAAP adjustment is evaluated to determine whether a discrete adjustment should be made to the adjusted income tax provision.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(9)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">In order to enhance the Company&#8217;s and investors&#8217; ability to set Adjusted EPS growth expectations for future periods, the Company adjusted its projected 2021 Adjusted EPS to remove the following items when determining baseline Adjusted EPS&#58; (i) the impact of items that it cannot project for future periods such as realized capital gains and losses and changes in prior years' health care costs estimates, (ii) including the estimated impact of the full year incremental expense related to our minimum wage increase and (iii) the corresponding tax benefit or expense per share related to the items excluded from or included in baseline Adjusted EPS above. Net realized capital gains and losses arise from various types of transactions, primarily in the course of managing a portfolio of assets that support the payment of insurance liabilities. The Company experiences net realized capital gains or net realized capital losses, however the Company cannot project the amount of such gains or losses. In addition, the Company experiences changes to its prior years&#8217; health care cost estimates, however the Company cannot project the amount of such changes in estimates. The Company is including the full year projected impact of the labor costs to make it comparable to future periods which will include a full year of the increased labor cost. When determining the income tax impact of the baseline Adjusted EPS adjustments, the nature of the total baseline adjustments were evaluated to determine whether a discrete adjustment should be made to the baseline income tax provision.</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.964%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.699%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ending December 31, 2022E</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Low</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">High</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In&#160;millions,&#160;except&#160;per&#160;share&#160;amounts</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total<br>Company</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Per<br>Common<br> Share</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total<br>Company</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Per<br>Common<br> Share</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations (GAAP measure)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,370&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.04&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,630&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.24&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Non-GAAP adjustments&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,870&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.41&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,870&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.41&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax impact of non-GAAP adjustments </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(470)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.35)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(470)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.35)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted income from continuing operations attributable to CVS Health</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,770&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.10&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,030&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.30&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average diluted common shares outstanding</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,330&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,330&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">           _____________________________________________</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Represents the corresponding tax benefit or expense related to the items excluded from Adjusted EPS above. The nature of each non-GAAP adjustment is evaluated to determine whether a discrete adjustment should be made to the adjusted income tax provision.</font></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>cvs-20211209.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:808506d9-5561-437f-804a-f951434e5e2c,g:b02a37d0-9816-4b0a-89e0-a8785715b411-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:cvs="http://www.cvshealth.com/20211209" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.cvshealth.com/20211209">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021" schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cvs-20211209_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cvs-20211209_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.cvshealth.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>cvs-20211209_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:808506d9-5561-437f-804a-f951434e5e2c,g:b02a37d0-9816-4b0a-89e0-a8785715b411-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_PreCommencementTenderOffer_cbfe3628-9eff-42b3-a60c-3d84e18b45a6_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_8c7caef9-d63e-4e36-8c70-027e3dd76077_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_ab44f30a-54c7-490f-bccd-3891ad7315a6_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_8b0a0bf9-f994-4b2b-95b9-844419b206a1_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_8ecc342c-8935-4d7a-a272-1ed501a12087_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_20ce0369-dc71-44e3-87c5-7ca5a93ea57b_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_62aec3a3-e385-4326-8c38-cc65031c2700_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_24138569-bb18-4913-a85c-c88a13c026f7_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_30270896-104f-42bf-a620-f94114140501_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_111a2aa3-0365-4fcc-8229-e0a7b88c2bed_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_cd969ded-30e0-45c6-abc6-5be9854a0a97_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_a50aeb3d-5442-4e3b-b036-44d403aad26f_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_92f30ad5-0f6f-4e3c-ae46-5c1301eea71b_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_5e584a52-8591-4b40-b14a-1283568c622f_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_a981d04a-54b9-4b12-a2c8-292bbd6d205f_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_1671cd24-3e14-4660-945e-6cd3afe126d3_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_bf946192-c4ba-482a-9bf6-794f43ca3eda_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_0470a933-9d64-4b16-9b2c-4784829e4acf_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_4dfb6e11-e10b-4da7-b7d3-512c01381d87_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_64cd1c37-6d56-43ea-a084-e412d4de6410_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_2317f768-ce47-44b0-896e-aaacee6386f7_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_eed8ae23-fbfb-41bc-a9da-cb4bfcc9ccae_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_57f3a878-b132-4987-9a42-13627e21134c_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>cvs-20211209_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:808506d9-5561-437f-804a-f951434e5e2c,g:b02a37d0-9816-4b0a-89e0-a8785715b411-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.cvshealth.com/role/CoverPage" xlink:type="simple" xlink:href="cvs-20211209.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.cvshealth.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_626c8f1f-48f6-409d-9e36-0e509e6023ae" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_8ac1f6c1-5284-4c28-b499-b7301eb1a38f" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_626c8f1f-48f6-409d-9e36-0e509e6023ae" xlink:to="loc_dei_DocumentType_8ac1f6c1-5284-4c28-b499-b7301eb1a38f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_cf39ef5b-03ef-4969-83b9-ea0058c4bea0" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_626c8f1f-48f6-409d-9e36-0e509e6023ae" xlink:to="loc_dei_DocumentPeriodEndDate_cf39ef5b-03ef-4969-83b9-ea0058c4bea0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_d3a3d5f5-9b6a-4b30-a065-1e3cb93473b6" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_626c8f1f-48f6-409d-9e36-0e509e6023ae" xlink:to="loc_dei_EntityRegistrantName_d3a3d5f5-9b6a-4b30-a065-1e3cb93473b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_84737805-8483-4178-b9d7-4a6963ef1ad2" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_626c8f1f-48f6-409d-9e36-0e509e6023ae" xlink:to="loc_dei_EntityCentralIndexKey_84737805-8483-4178-b9d7-4a6963ef1ad2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_5f0f2e42-710c-4130-8a59-a6756ab0d5fa" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_626c8f1f-48f6-409d-9e36-0e509e6023ae" xlink:to="loc_dei_AmendmentFlag_5f0f2e42-710c-4130-8a59-a6756ab0d5fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_c352ea98-6685-4388-a656-020e890e3038" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_626c8f1f-48f6-409d-9e36-0e509e6023ae" xlink:to="loc_dei_EntityIncorporationStateCountryCode_c352ea98-6685-4388-a656-020e890e3038" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_e83dbd6d-d5a1-43f8-becf-80d43951b464" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_626c8f1f-48f6-409d-9e36-0e509e6023ae" xlink:to="loc_dei_EntityFileNumber_e83dbd6d-d5a1-43f8-becf-80d43951b464" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_19cf3be0-eb08-49a2-bae7-42234cf28226" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_626c8f1f-48f6-409d-9e36-0e509e6023ae" xlink:to="loc_dei_EntityTaxIdentificationNumber_19cf3be0-eb08-49a2-bae7-42234cf28226" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_704673d1-22ee-4f36-aacd-35679498b771" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_626c8f1f-48f6-409d-9e36-0e509e6023ae" xlink:to="loc_dei_EntityAddressAddressLine1_704673d1-22ee-4f36-aacd-35679498b771" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_83a445b5-34a5-4fdf-a1b6-426a0e61ae02" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_626c8f1f-48f6-409d-9e36-0e509e6023ae" xlink:to="loc_dei_EntityAddressCityOrTown_83a445b5-34a5-4fdf-a1b6-426a0e61ae02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_439fa519-f536-4119-a792-e6ed8635b2f5" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_626c8f1f-48f6-409d-9e36-0e509e6023ae" xlink:to="loc_dei_EntityAddressStateOrProvince_439fa519-f536-4119-a792-e6ed8635b2f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_500ff99e-a223-48fe-b4d3-bc84ef6c5fe0" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_626c8f1f-48f6-409d-9e36-0e509e6023ae" xlink:to="loc_dei_EntityAddressPostalZipCode_500ff99e-a223-48fe-b4d3-bc84ef6c5fe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_f64be4ef-460b-44cc-9fcf-fd17a82e1fc4" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_626c8f1f-48f6-409d-9e36-0e509e6023ae" xlink:to="loc_dei_CityAreaCode_f64be4ef-460b-44cc-9fcf-fd17a82e1fc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_949803cd-5739-434e-bec5-92afde166e4a" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_626c8f1f-48f6-409d-9e36-0e509e6023ae" xlink:to="loc_dei_LocalPhoneNumber_949803cd-5739-434e-bec5-92afde166e4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_c7890962-2396-44c2-b87a-36fb5b06461c" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_626c8f1f-48f6-409d-9e36-0e509e6023ae" xlink:to="loc_dei_WrittenCommunications_c7890962-2396-44c2-b87a-36fb5b06461c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_393b033b-7ad1-4d6e-a173-66afd73462e5" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_626c8f1f-48f6-409d-9e36-0e509e6023ae" xlink:to="loc_dei_SolicitingMaterial_393b033b-7ad1-4d6e-a173-66afd73462e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_44303387-5288-4d63-81ea-df5241d56aec" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_626c8f1f-48f6-409d-9e36-0e509e6023ae" xlink:to="loc_dei_PreCommencementTenderOffer_44303387-5288-4d63-81ea-df5241d56aec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_a7c2ad80-bbd5-423b-a1b5-4aa1f4f23a0b" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_626c8f1f-48f6-409d-9e36-0e509e6023ae" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_a7c2ad80-bbd5-423b-a1b5-4aa1f4f23a0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_bdad7d8a-2e02-4fbd-8fe6-57846faee022" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_626c8f1f-48f6-409d-9e36-0e509e6023ae" xlink:to="loc_dei_Security12bTitle_bdad7d8a-2e02-4fbd-8fe6-57846faee022" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_8453628b-075c-4ff2-bb50-cdb346fb4740" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_626c8f1f-48f6-409d-9e36-0e509e6023ae" xlink:to="loc_dei_TradingSymbol_8453628b-075c-4ff2-bb50-cdb346fb4740" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_0250ade8-04e0-4c21-8df7-9b85a0be4ae4" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_626c8f1f-48f6-409d-9e36-0e509e6023ae" xlink:to="loc_dei_SecurityExchangeName_0250ade8-04e0-4c21-8df7-9b85a0be4ae4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_1a115004-b389-4c9c-a871-6033d776d141" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_626c8f1f-48f6-409d-9e36-0e509e6023ae" xlink:to="loc_dei_EntityEmergingGrowthCompany_1a115004-b389-4c9c-a871-6033d776d141" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>cvs-20211209_g1.jpg
<DESCRIPTION>CVS HEALTH LOGO
<TEXT>
begin 644 cvs-20211209_g1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1"  < )T# 2(  A$! Q$!_\0
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M>(O@BW@63PU_PLX3?\([?_V@?#O]N&P_L[S/M.S[=Y()\[9Y>[G;CY3\[?\
M! #X'?M5>,O^"27PGU+X;?'KX=^"_!=U_;!T[1M2^'?]K7=IMUJ^67?<_:X_
M,WS"1Q\@VJRKR5R?0/V=/#OQ/^$G_!QY=?\ "Y_'WA_XAZ];_LT3WB:GHWAP
MZ)#!8CQ*-L+0>;,7=765MX9<AU&!LRWUA_+9^KB_+[#WIQ;!QW]/\_6OY[?V
M;OVJ_P!C_P#X*)>#M0^+7[;WC_XA>+OB%XMUB[O-*\%V]AXMC\/_  ZL(KAX
MK6TL3I4*PRN8T21YMS,Q9=P$JRM)W'P;_P""O^L?L<_LH_MF:9\-/''B_P"+
M?@#X3:7H^J?"3Q+XKT^^35-+75;B'3I+.X:_BC>>.QNKB)H5=#N2-QN*LJ1@
M'[M#FOFC_@KA\;/BE^S3^PSXP^)'PEU#P78ZY\/[6;Q!J,?B739[ZWO["WMI
MWD@B6*6,I,T@A*NQ*@*P(R01\_?#+_@W<\ Q?"VQ\0^*O'7Q7OOVEKG3UFO?
MBS!XWU)=8L=3*J7:WC$PMS;(X*)%)$^8OE+$_/7QW^QC\-]8_P"'!O[<?C;Q
MWK&L>(?BE?3^+O#WB'4)]6N)K23[%&6VP6[-Y$($TTQ!CB0E6"] H !^G&E_
M\%(M%^&?[.G[+_B+XA66I2>(OVC9/#^AVG]A60-I;:MJ5BEQEP\H:.WW[P#F
M1E!'!P2.+_:0_:[^,7P$_P""P'[//PK:\\!WOPB^.XUY([<:3.-<TY])TE;E
M]]QYWE,LD\J%0L0VJI!R3D_#7[>W['O@KXH?!'_@F;XDU9/$+:EXRUKP#X,U
M/[+KU[:0OI[::93Y4<4JK!/N8_OX@LV, .!7JO\ P5C_ &0+37O^"A'_  3E
M^#?A7Q1XN\#Z+%#XVTI-5TW5IVUB'3H=*T]KF);N1FF$D]LDT!E+%AYQ;)(Y
M /UF3CKG/H?6G9S7Y/?M7?L8>#?^"*WQ_P#V;?B-^SRWB7P38?$KXN:/\./&
M_AF7Q#J.K:5XGL]4$X:YE2[GD(NH!"3$ZL "YSD##?J_'N ^:@".6 RQ[3T/
M%?E7^W5_P;TW'Q._:+TO7OA+?:-X9\+>++PCQ)I\X*Q>'R07>ZM(E&'1\$?9
MP5"RLFUEC8F']6J*Y<5@Z6(AR55='U'"O&.;<.XF6*RJKR2DFGU33[IZ.VZ[
M,\S_ &5?V5/!_P"QW\'M/\%>"=-^PZ79?O)I9<-<W\YQON)W &^5\#)X  55
M"JJJ/&O^"JO_  3,L?\ @H?\+-/6QOH-#\=>%7EFT34)T9K9Q(%\RVG"_-Y3
ME(SN +(R*P##<C?6-%54PM*=+V#7NVM8X\OXDS+!YFLXH57[=/FYF[MM[WOO
M?5.^]S\'S_P2 _;*T?PY-\.K>XNF\$7$VZ6SA\9[="F)?>7-N6!.7^<Y@!+9
M."V,_HU_P2:_X)<_\.]_A[KTWB#5+'7O'/BXQ#4KFS5_LEG#$'\N"$N S -(
M[,Y5"^X?* B@?8U%<.%R>A0J>TC=OI?6WH?:<3>+F>9W@I9?75.G3G+FG[."
MBYM6UD^NJ1^'WQA_X-V?C%?_ !L\2+X3D\%6O@N\UF=](DFU%Q+:6,DK-$K1
M^426BC8*?F.2@K]#/^"@'_!+G1?VNOV.M!^&^@SVOAV^\!I;OX6EECWV]N88
M#"+>7 W")XSM+*"58(^U]FQOK6BJHY1AJ2FH+26YSYQXK<0YE4PE;$5%S87X
M&EUTUE_,[*VO2_<_"FP_X)/?MJ> _!&H?#/2;B=/ NH2.MS9V'BV./2+D.<R
M'RV>.54DR2R>6 V3N!).?L_]@G_@FU\3/^":G[,GCW7/#%KX/\>_'#Q6UDL6
MEWFHRV.AP013[3%]J\HREA%+-(7\L!F2) N$WO\ H/12PN3T*%158MMK:[V-
MN)?%K.\ZP,\NKJG3IS:E/V<%%S:U]Y]=5<^'_P#@@O\ LL?&S]AC]BG3?@U\
M7/#_ (,TVS\"F7^PM2T/6I-0FU7[7?WMY<>?&T*+"8S-"B%6?<"Q.TC!X:;]
MFK]J:7_@MK'\?O\ A7_PJ_X5^GA;_A5A4^+)FO/[!.NF].J"+[-C[7Y!/^C$
M^7GCS.<U^C-%>J?F)^;W[.7[._[5'_!(K0]8^%OPE^''@G]H3X%_VQ=7_@F&
MZ\9CPOKW@ZVNIFGELKIIX)HKJ&.61RDB_O&)=FP&2*/TV/\ 8.^+G[;O[&GQ
MD\#_ +57C'P_<W'QAC6/3?#GA6R1M(^'<4.)+3[/.T<=S>7"SI#/*T[&,O"$
MC"IN+_:E% 'YY_#36?\ @H=\//A)9_".Z\ _!G7?$6EV4>E6GQEG\82_V>\*
M(B)=7&D-;FYFO-@+/ATB>7MLR&\Z_82_X))_'+X/?\$S?VCOV8?&UQX5:U\>
M)K<OA;QBNK27$^JW-_&T0>^M_*)@'[J%V*R2G]ZX&64,?U1HH _+KXA_L)?M
M/?%[]@O]F^QO/"/PYT?XK?LL^.]"U;3=&/B>2?3/%VFZ38);K)]H$.;>>:4L
M1&P941"2S$A:V?VLO@#^UY\=?VX?V9_C-H_PJ^$]O_PH^PU6YGTF[\=SK]KO
M-9TR"VN[=I%LSM6UD1]LBA_-Z[5'%?I910!\'_\ !:3]EWX]?M9:K\$[/X2^
M$_ NL:3\,?B!I/Q)N;G7/$<NFRW%WISS[+$1K!(/+D64$R[\J5QL/!'VO\.[
MS7-1\!Z+<>)=/L=)\17%A;R:I965V;NUM+MHU,T<4K(C2(LA95<HI8*&VJ20
&-FB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>cvslogoa.jpg
<DESCRIPTION>CVS HEALTH LOGO
<TEXT>
begin 644 cvslogoa.jpg
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M#?OT,>(?T+\//3WU"3&FVO!CMG+E%9?Q3*6)U/?JMJWH[ZV;I>Q@2>!IGNG
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M;[4N0,7R%K& 6T-9=^(*ZG8MSY*LJ2T_$=8GH/Z/^$2[;QTK.Y%$=ZA/*,D
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MY>/P&0 7"?#A@G=%!]AJB?OP__^[[QX9_7L;7#?PM"MV&S5KVEC(!V1X)I$
MR!AK =A5A(5D(%A=8!T'82<\[:AY$77M'.E97ZF(;D.-T), H)1=?8C @0#\
MO)Q<((NN:M]\!-PGG-X-"51V8;BR*"FBE)E/!SZWH>JZ\[HAL@<_8SE>4!/!
MU_R0'7\O!\2ZVG8%*3TYPM9VO&_X^ ]+Y4!88G0_(019W!5"0-X@A4K.$B0=
M\NE,69NL@T#>^M</G3<)X"$]'><$='T0]D&[@F LZ_#,Y(O/%\NURF+=;VLY
M7^W;MMKZ[--3Y1K*QT+Q;=QV?*^) J>2EWUC$86N:T6 74,X;P#7$O1P9I&
M9;1QX*LR1GO,:&Z'SJ]637EM9OJQT+XPOS*H&A( E,)//Q$XS0 "$ "@KLD6
MT8$NW^4+(XDMHMU[V;:(5N0!0AJ4[U84E,X1ECDNT *O^A[W96_]C5*?GTDQ
MEU_COX]PGJ)Q!.V]ZTZ)%>0:=CV7Y(N[)F/99W1@RF,\:[E.0FS@; +REAF,
MQVW$$BPAR$PEP@H&Z #]T)4C 7Y(3\>)87TO]MQC](VZ8"$7=<.61H0K.)&9
M*>ZB8.7$"4['Z9-V),J^>.N@4SU9F+U[HC7+ ' :MGLWM8C+Y6.[;.M6+>3
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MWKL1BMH6TMH.3[<5R4XB5^'*05C-F2#[#J3\?>JUGK;^KZXD,&OZ,YYME')
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MG2R&TAN5-11([YT'1MXI;%QW)R?1_KU[''<LA<I  4[M_Z<C4)M#J=_J3P)
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'14Y$KD)@@@$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>cvs-20211209_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="cvs-20211209.xsd" xlink:type="simple"/>
    <context id="ideab86f3595e4e809f335201713c0416_D20211209-20211209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
        </entity>
        <period>
            <startDate>2021-12-09</startDate>
            <endDate>2021-12-09</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="ideab86f3595e4e809f335201713c0416_D20211209-20211209"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkZTA1Yzk5ZGRkODRhYTNiN2Y0ZmM4MjU5NGY1YzQzL3NlYzpmZGUwNWM5OWRkZDg0YWEzYjdmNGZjODI1OTRmNWM0M180L2ZyYWc6OWFlNWRmMGU5YTYyNDQyY2I2ZDQ0NjJmMTVjM2Y1ZDkvdGFibGU6NzIxOTg2NzIwYWNhNDQ5MmFkMzU4ZTI4NDhjYjE3Y2IvdGFibGVyYW5nZTo3MjE5ODY3MjBhY2E0NDkyYWQzNThlMjg0OGNiMTdjYl8yLTEtMS0xLTQ0ODEx_50b0e279-88b2-46e6-b18b-6ed6344d1bf4">0000064803</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="ideab86f3595e4e809f335201713c0416_D20211209-20211209"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkZTA1Yzk5ZGRkODRhYTNiN2Y0ZmM4MjU5NGY1YzQzL3NlYzpmZGUwNWM5OWRkZDg0YWEzYjdmNGZjODI1OTRmNWM0M180L2ZyYWc6OWFlNWRmMGU5YTYyNDQyY2I2ZDQ0NjJmMTVjM2Y1ZDkvdGFibGU6NzIxOTg2NzIwYWNhNDQ5MmFkMzU4ZTI4NDhjYjE3Y2IvdGFibGVyYW5nZTo3MjE5ODY3MjBhY2E0NDkyYWQzNThlMjg0OGNiMTdjYl8zLTEtMS0xLTQ0ODEx_ac003abf-35c2-4c8f-9aa5-7e13e4f2fe72">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="ideab86f3595e4e809f335201713c0416_D20211209-20211209"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkZTA1Yzk5ZGRkODRhYTNiN2Y0ZmM4MjU5NGY1YzQzL3NlYzpmZGUwNWM5OWRkZDg0YWEzYjdmNGZjODI1OTRmNWM0M18xL2ZyYWc6OTU3ZjcyNDA0NmZhNDNkNzljN2I1MTNjM2JlOGQzOGQvdGV4dHJlZ2lvbjo5NTdmNzI0MDQ2ZmE0M2Q3OWM3YjUxM2MzYmU4ZDM4ZF8xMzc0_7b501f36-cdc9-4786-87ec-0445cc3cd6b4">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="ideab86f3595e4e809f335201713c0416_D20211209-20211209"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkZTA1Yzk5ZGRkODRhYTNiN2Y0ZmM4MjU5NGY1YzQzL3NlYzpmZGUwNWM5OWRkZDg0YWEzYjdmNGZjODI1OTRmNWM0M18xL2ZyYWc6OTU3ZjcyNDA0NmZhNDNkNzljN2I1MTNjM2JlOGQzOGQvdGFibGU6ODI4N2JmMTg4ODBhNDMxNWFiOTJjZTIxN2M1YWEyM2MvdGFibGVyYW5nZTo4Mjg3YmYxODg4MGE0MzE1YWI5MmNlMjE3YzVhYTIzY18wLTEtMS0xLTQ0ODEx_bac45ecc-245d-41e3-8e8d-559129c55d0e">2021-12-09</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="ideab86f3595e4e809f335201713c0416_D20211209-20211209"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkZTA1Yzk5ZGRkODRhYTNiN2Y0ZmM4MjU5NGY1YzQzL3NlYzpmZGUwNWM5OWRkZDg0YWEzYjdmNGZjODI1OTRmNWM0M18xL2ZyYWc6OTU3ZjcyNDA0NmZhNDNkNzljN2I1MTNjM2JlOGQzOGQvdGV4dHJlZ2lvbjo5NTdmNzI0MDQ2ZmE0M2Q3OWM3YjUxM2MzYmU4ZDM4ZF8xMzc1_8b0c809c-1f5f-42f9-b75a-7b9a786205b4">CVS HEALTH CORP</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="ideab86f3595e4e809f335201713c0416_D20211209-20211209"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkZTA1Yzk5ZGRkODRhYTNiN2Y0ZmM4MjU5NGY1YzQzL3NlYzpmZGUwNWM5OWRkZDg0YWEzYjdmNGZjODI1OTRmNWM0M18xL2ZyYWc6OTU3ZjcyNDA0NmZhNDNkNzljN2I1MTNjM2JlOGQzOGQvdGFibGU6OGVkZmRiMTUyOWM1NDlmMzg1ZWVjNGRlODYxN2QxMGIvdGFibGVyYW5nZTo4ZWRmZGIxNTI5YzU0OWYzODVlZWM0ZGU4NjE3ZDEwYl8wLTAtMS0xLTQ0ODEx_c0920fed-dd4b-4b05-9f60-5ceda3ccf9da">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="ideab86f3595e4e809f335201713c0416_D20211209-20211209"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkZTA1Yzk5ZGRkODRhYTNiN2Y0ZmM4MjU5NGY1YzQzL3NlYzpmZGUwNWM5OWRkZDg0YWEzYjdmNGZjODI1OTRmNWM0M18xL2ZyYWc6OTU3ZjcyNDA0NmZhNDNkNzljN2I1MTNjM2JlOGQzOGQvdGFibGU6OGVkZmRiMTUyOWM1NDlmMzg1ZWVjNGRlODYxN2QxMGIvdGFibGVyYW5nZTo4ZWRmZGIxNTI5YzU0OWYzODVlZWM0ZGU4NjE3ZDEwYl8wLTEtMS0xLTQ0ODEx_1f3b9081-6064-4bda-b51d-58969f60bae5">001-01011</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="ideab86f3595e4e809f335201713c0416_D20211209-20211209"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkZTA1Yzk5ZGRkODRhYTNiN2Y0ZmM4MjU5NGY1YzQzL3NlYzpmZGUwNWM5OWRkZDg0YWEzYjdmNGZjODI1OTRmNWM0M18xL2ZyYWc6OTU3ZjcyNDA0NmZhNDNkNzljN2I1MTNjM2JlOGQzOGQvdGFibGU6OGVkZmRiMTUyOWM1NDlmMzg1ZWVjNGRlODYxN2QxMGIvdGFibGVyYW5nZTo4ZWRmZGIxNTI5YzU0OWYzODVlZWM0ZGU4NjE3ZDEwYl8wLTItMS0xLTQ0ODEx_311fae58-c9a5-4b0a-a14f-5e9514212dab">05-0494040</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="ideab86f3595e4e809f335201713c0416_D20211209-20211209"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkZTA1Yzk5ZGRkODRhYTNiN2Y0ZmM4MjU5NGY1YzQzL3NlYzpmZGUwNWM5OWRkZDg0YWEzYjdmNGZjODI1OTRmNWM0M18xL2ZyYWc6OTU3ZjcyNDA0NmZhNDNkNzljN2I1MTNjM2JlOGQzOGQvdGV4dHJlZ2lvbjo5NTdmNzI0MDQ2ZmE0M2Q3OWM3YjUxM2MzYmU4ZDM4ZF8xMzc2_0973c498-6e59-4cf8-8262-10169fc2cd1d">One CVS Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="ideab86f3595e4e809f335201713c0416_D20211209-20211209"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkZTA1Yzk5ZGRkODRhYTNiN2Y0ZmM4MjU5NGY1YzQzL3NlYzpmZGUwNWM5OWRkZDg0YWEzYjdmNGZjODI1OTRmNWM0M18xL2ZyYWc6OTU3ZjcyNDA0NmZhNDNkNzljN2I1MTNjM2JlOGQzOGQvdGV4dHJlZ2lvbjo5NTdmNzI0MDQ2ZmE0M2Q3OWM3YjUxM2MzYmU4ZDM4ZF8xMzc3_01f41b2e-5e5a-40d4-a889-43840138d94c">Woonsocket</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="ideab86f3595e4e809f335201713c0416_D20211209-20211209"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkZTA1Yzk5ZGRkODRhYTNiN2Y0ZmM4MjU5NGY1YzQzL3NlYzpmZGUwNWM5OWRkZDg0YWEzYjdmNGZjODI1OTRmNWM0M18xL2ZyYWc6OTU3ZjcyNDA0NmZhNDNkNzljN2I1MTNjM2JlOGQzOGQvdGV4dHJlZ2lvbjo5NTdmNzI0MDQ2ZmE0M2Q3OWM3YjUxM2MzYmU4ZDM4ZF8xMzc4_8c76a650-8cf9-4e85-ad16-4136b288d30d">RI</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="ideab86f3595e4e809f335201713c0416_D20211209-20211209"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkZTA1Yzk5ZGRkODRhYTNiN2Y0ZmM4MjU5NGY1YzQzL3NlYzpmZGUwNWM5OWRkZDg0YWEzYjdmNGZjODI1OTRmNWM0M18xL2ZyYWc6OTU3ZjcyNDA0NmZhNDNkNzljN2I1MTNjM2JlOGQzOGQvdGV4dHJlZ2lvbjo5NTdmNzI0MDQ2ZmE0M2Q3OWM3YjUxM2MzYmU4ZDM4ZF8xMzc5_2c22e312-e630-4744-be40-8a15aa665479">02895</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="ideab86f3595e4e809f335201713c0416_D20211209-20211209"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkZTA1Yzk5ZGRkODRhYTNiN2Y0ZmM4MjU5NGY1YzQzL3NlYzpmZGUwNWM5OWRkZDg0YWEzYjdmNGZjODI1OTRmNWM0M18xL2ZyYWc6OTU3ZjcyNDA0NmZhNDNkNzljN2I1MTNjM2JlOGQzOGQvdGV4dHJlZ2lvbjo5NTdmNzI0MDQ2ZmE0M2Q3OWM3YjUxM2MzYmU4ZDM4ZF8xMzgz_9f5ba687-0cb3-4da6-81ef-4f4d6a60b2e5">401</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="ideab86f3595e4e809f335201713c0416_D20211209-20211209"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkZTA1Yzk5ZGRkODRhYTNiN2Y0ZmM4MjU5NGY1YzQzL3NlYzpmZGUwNWM5OWRkZDg0YWEzYjdmNGZjODI1OTRmNWM0M18xL2ZyYWc6OTU3ZjcyNDA0NmZhNDNkNzljN2I1MTNjM2JlOGQzOGQvdGV4dHJlZ2lvbjo5NTdmNzI0MDQ2ZmE0M2Q3OWM3YjUxM2MzYmU4ZDM4ZF8xMzgw_9cd21e76-4148-419f-acdd-52bff4715f98">765-1500</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="ideab86f3595e4e809f335201713c0416_D20211209-20211209"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkZTA1Yzk5ZGRkODRhYTNiN2Y0ZmM4MjU5NGY1YzQzL3NlYzpmZGUwNWM5OWRkZDg0YWEzYjdmNGZjODI1OTRmNWM0M18xL2ZyYWc6OTU3ZjcyNDA0NmZhNDNkNzljN2I1MTNjM2JlOGQzOGQvdGV4dHJlZ2lvbjo5NTdmNzI0MDQ2ZmE0M2Q3OWM3YjUxM2MzYmU4ZDM4ZF8xMzcz_28f1be83-ead2-43d7-8b0b-84615347085e">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="ideab86f3595e4e809f335201713c0416_D20211209-20211209"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkZTA1Yzk5ZGRkODRhYTNiN2Y0ZmM4MjU5NGY1YzQzL3NlYzpmZGUwNWM5OWRkZDg0YWEzYjdmNGZjODI1OTRmNWM0M18xL2ZyYWc6OTU3ZjcyNDA0NmZhNDNkNzljN2I1MTNjM2JlOGQzOGQvdGV4dHJlZ2lvbjo5NTdmNzI0MDQ2ZmE0M2Q3OWM3YjUxM2MzYmU4ZDM4ZF8xMzgx_185948a7-60a6-4be0-962b-94f4226bd6a3">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="ideab86f3595e4e809f335201713c0416_D20211209-20211209"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkZTA1Yzk5ZGRkODRhYTNiN2Y0ZmM4MjU5NGY1YzQzL3NlYzpmZGUwNWM5OWRkZDg0YWEzYjdmNGZjODI1OTRmNWM0M18xL2ZyYWc6OTU3ZjcyNDA0NmZhNDNkNzljN2I1MTNjM2JlOGQzOGQvdGV4dHJlZ2lvbjo5NTdmNzI0MDQ2ZmE0M2Q3OWM3YjUxM2MzYmU4ZDM4ZF8xMzgy_1e627925-761f-4801-9be4-0b56d1df1dc1">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="ideab86f3595e4e809f335201713c0416_D20211209-20211209"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkZTA1Yzk5ZGRkODRhYTNiN2Y0ZmM4MjU5NGY1YzQzL3NlYzpmZGUwNWM5OWRkZDg0YWEzYjdmNGZjODI1OTRmNWM0M18xL2ZyYWc6OTU3ZjcyNDA0NmZhNDNkNzljN2I1MTNjM2JlOGQzOGQvdGV4dHJlZ2lvbjo5NTdmNzI0MDQ2ZmE0M2Q3OWM3YjUxM2MzYmU4ZDM4ZF8xMzg0_dd07e0d3-45b9-4bb2-975f-9da072a5e5e6">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="ideab86f3595e4e809f335201713c0416_D20211209-20211209"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkZTA1Yzk5ZGRkODRhYTNiN2Y0ZmM4MjU5NGY1YzQzL3NlYzpmZGUwNWM5OWRkZDg0YWEzYjdmNGZjODI1OTRmNWM0M18xL2ZyYWc6OTU3ZjcyNDA0NmZhNDNkNzljN2I1MTNjM2JlOGQzOGQvdGFibGU6YmY5NTA1MDJhNzNiNGI4Mjg0MWI2ZGQ3ZjFiZDFlMjgvdGFibGVyYW5nZTpiZjk1MDUwMmE3M2I0YjgyODQxYjZkZDdmMWJkMWUyOF8xLTAtMS0xLTQ0ODEx_62cad84b-6145-4a40-b525-fb62a9ae8469">Common Stock, par value $0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ideab86f3595e4e809f335201713c0416_D20211209-20211209"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkZTA1Yzk5ZGRkODRhYTNiN2Y0ZmM4MjU5NGY1YzQzL3NlYzpmZGUwNWM5OWRkZDg0YWEzYjdmNGZjODI1OTRmNWM0M18xL2ZyYWc6OTU3ZjcyNDA0NmZhNDNkNzljN2I1MTNjM2JlOGQzOGQvdGFibGU6YmY5NTA1MDJhNzNiNGI4Mjg0MWI2ZGQ3ZjFiZDFlMjgvdGFibGVyYW5nZTpiZjk1MDUwMmE3M2I0YjgyODQxYjZkZDdmMWJkMWUyOF8xLTEtMS0xLTQ0ODEx_833b42cd-b239-481d-be14-ba0cae3431e5">CVS</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ideab86f3595e4e809f335201713c0416_D20211209-20211209"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkZTA1Yzk5ZGRkODRhYTNiN2Y0ZmM4MjU5NGY1YzQzL3NlYzpmZGUwNWM5OWRkZDg0YWEzYjdmNGZjODI1OTRmNWM0M18xL2ZyYWc6OTU3ZjcyNDA0NmZhNDNkNzljN2I1MTNjM2JlOGQzOGQvdGFibGU6YmY5NTA1MDJhNzNiNGI4Mjg0MWI2ZGQ3ZjFiZDFlMjgvdGFibGVyYW5nZTpiZjk1MDUwMmE3M2I0YjgyODQxYjZkZDdmMWJkMWUyOF8xLTItMS0xLTQ0ODEx_7111304a-838d-4fcf-a4f2-7fde8b1f202d">NYSE</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="ideab86f3595e4e809f335201713c0416_D20211209-20211209"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkZTA1Yzk5ZGRkODRhYTNiN2Y0ZmM4MjU5NGY1YzQzL3NlYzpmZGUwNWM5OWRkZDg0YWEzYjdmNGZjODI1OTRmNWM0M18xL2ZyYWc6OTU3ZjcyNDA0NmZhNDNkNzljN2I1MTNjM2JlOGQzOGQvdGFibGU6MDZjOGRjYmI5MzNkNDhjYzlhOGVlYWM0MWVhN2IxMjMvdGFibGVyYW5nZTowNmM4ZGNiYjkzM2Q0OGNjOWE4ZWVhYzQxZWE3YjEyM18wLTEtMS0xLTQ0ODEx_d669873c-9ea4-4fee-82d2-7a889341d821">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140096625333304">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover Page<br></strong></div></th>
<th class="th"><div>Dec. 09, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec.  09,  2021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CVS HEALTH CORP<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000064803<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-01011<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">05-0494040<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">One CVS Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Woonsocket<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">RI<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02895<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">401<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">765-1500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.01 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CVS<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M$<+NOS^QO-9.&G_FB^$_7G\!4$L! A0#%     @ :#6)4P=!36*!    L0
M !               ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4
M" !H-8E3+V-S=>X    K @  $0              @ &O    9&]C4')O<',O
M8V]R92YX;6Q02P$"% ,4    " !H-8E3F5R<(Q &  "<)P  $P
M    @ ', 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( &@UB5.Q
M:H8 )P0  "<0   8              " @0T(  !X;"]W;W)K<VAE971S+W-H
M965T,2YX;6Q02P$"% ,4    " !H-8E3GZ ;\+$"  #B#   #0
M    @ %J#   >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( &@UB5.7BKL<P
M !,"   +              "  48/  !?<F5L<R\N<F5L<U!+ 0(4 Q0    (
M &@UB5,9117U-P$  "<"   /              "  2\0  !X;"]W;W)K8F]O
M:RYX;6Q02P$"% ,4    " !H-8E3)!Z;HJT   #X 0  &@
M@ &3$0  >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " !H
M-8E399!YDAD!  #/ P  $P              @ %X$@  6T-O;G1E;G1?5'EP
=97-=+GAM;%!+!08     "0 ) #X"  #"$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>96</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="cvs-20211209.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvshealth.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="cvs-20211209.htm">cvs-20211209.htm</File>
    <File>cvs-20211209.xsd</File>
    <File>cvs-20211209_lab.xml</File>
    <File>cvs-20211209_pre.xml</File>
    <File>cvs_ex99x1xinvestorday.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>cvs-20211209_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "cvs-20211209.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "cvs-20211209.htm"
     ]
    },
    "labelLink": {
     "local": [
      "cvs-20211209_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cvs-20211209_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "cvs-20211209.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 23,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 96,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "cvs",
   "nsuri": "http://www.cvshealth.com/20211209",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvs-20211209.htm",
      "contextRef": "ideab86f3595e4e809f335201713c0416_D20211209-20211209",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://www.cvshealth.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvs-20211209.htm",
      "contextRef": "ideab86f3595e4e809f335201713c0416_D20211209-20211209",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.cvshealth.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.cvshealth.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.cvshealth.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.cvshealth.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.cvshealth.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.cvshealth.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.cvshealth.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.cvshealth.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.cvshealth.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.cvshealth.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.cvshealth.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.cvshealth.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.cvshealth.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.cvshealth.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.cvshealth.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.cvshealth.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.cvshealth.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.cvshealth.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.cvshealth.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.cvshealth.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.cvshealth.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.cvshealth.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0000064803-21-000036-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000064803-21-000036-xbrl.zip
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M+$CN*,F[7#"G/9X^1JT2A8ZGA=*SF#VZE=E[\DA82_3\6$8PDP:4O$HY^B8
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M4#,T!J&#R<Q.8S&G=SS7\[[O/^\?[_-\U[VNM:[KOG]K_3[W]W>O=0L_"AG
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M*JDL+*1VMC1W!O]C5,.U<9\]02OH_('*I#1:Q5US$:N0^E]02P,$%     @
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M!V_3\3/SZNV+S3OIZMGC;U_\'U!+ P04    " !H-8E38339G*L&  #I,
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M%1Z*,JFOWG^T95);K$3<^X_:TOG)>&RUGU 8HKT$;!\OX#D8#GR\(->R>;C
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M&12KI<(Z@#[PR*96R+P#&V (+Q&"LPG/2%4!%5U$,E> XJ4F540#\ !?D+#
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M*Y%CI<YO(ML$L.!5F-I+&,$%UXQEBQD>U0!04F 83H<] $F ^12> $UN+(<
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MX0+^-\FF\8__#U!+ 0(4 Q0    ( &@UB5/OGY4!WQ0  ).#   0
M      "  0    !C=G,M,C R,3$R,#DN:'1M4$L! A0#%     @ :#6)4Y'8
M6V=R @  >P<  !               ( !#14  &-V<RTR,#(Q,3(P.2YX<V10
M2P$"% ,4    " !H-8E31__R*<0.  !^#P  $P              @ &M%P
M8W9S+3(P,C$Q,C Y7V<Q+FIP9U!+ 0(4 Q0    ( &@UB5-Q/V.D=PH  $E>
M   4              "  :(F  !C=G,M,C R,3$R,#E?;&%B+GAM;%!+ 0(4
M Q0    ( &@UB5-A--F<JP8  .DP   4              "  4LQ  !C=G,M
M,C R,3$R,#E?<')E+GAM;%!+ 0(4 Q0    ( &@UB5/XOEOL8"\  (I< @ :
M              "  2@X  !C=G-?97@Y.7@Q>&EN=F5S=&]R9&%Y+FAT;5!+
4!08     !@ & (D!  # 9P     !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
